Cortagen: Research Overview

Cortagen is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Pro (AEDP). It was developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson through directed synthesis from amino acid analysis of Cortexin, a natural polypeptide complex derived from bovine cerebral cortex. Cortagen has no FDA, EMA, or comparable Western regulatory approval and is not cleared as a pharmaceutical outside Russia. It is classified as a brain-targeted peptide bioregulator within the Khavinson system.

What is Cortagen?

Cortagen is the synthetic minimal-sequence analog derived from Cortexin, which is itself an approved Russian pharmaceutical used in neurology. By contrast, Cortagen as a standalone tetrapeptide is a research compound rather than a registered medicine. Within the Khavinson bioregulator framework, it is hypothesized to act selectively on neurons and cortical tissue, influencing gene expression in a manner consistent with the tissue of its origin.

Proposed Mechanism

Electrophysiological studies in animal models have reported that Cortagen hyperpolarizes neurons and reduces their spontaneous firing rate, an effect interpreted as neuroprotective stabilization of resting membrane potential. Separately, the Khavinson group's epigenetic model proposes that the AEDP sequence binds DNA regulatory elements in neurons, decondensing heterochromatin and facilitating transcription of genes involved in neuronal maintenance and repair. In rodent sciatic-nerve regeneration models, Cortagen administration was reportedly associated with accelerated early nerve fiber growth. These are mechanistic hypotheses from animal and cell data only; no corresponding human mechanistic data exist.

Research Summary

The most frequently cited PubMed-indexed Cortagen study is Anisimov and Khavinson et al. (2004, PMID 15159690), which used cDNA microarrays to analyze the effect of a 5-day Cortagen injection course on gene expression across 15,247 transcripts in mouse cardiac tissue. The study identified 234 transcripts with significant expression changes, including genes involved in development, stress response, and signal transduction such as Bmp2, Wnt4, and Hsc70. A paper by the same group examined epigenetic regulation of heterochromatin by Cortagen in aged cell models, published in the International Journal of Peptide Research and Therapeutics (Springer, 2014).

Research on Cortagen is concentrated in a single Russian research group; independent Western replication is limited. The 2004 microarray study was conducted in mouse heart — a tissue not directly aligned with Cortagen's purported cortical-brain target — illustrating the exploratory rather than organ-specific nature of much of this work. No human clinical trials have been registered or reported in peer-reviewed Western journals.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

No formally validated human dose has been established. Russian-language supplement documentation references subcutaneous or intramuscular doses of approximately 0.5-1 mg per day administered over a 10-day course, with courses repeated once or twice per year. No dose-finding or safety studies in humans have been conducted under Western regulatory frameworks.

Frequently Asked Questions

Is Cortagen the same as Cortexin?

No. Cortexin is a complex polypeptide extract from bovine brain approved as a pharmaceutical in Russia for neurological conditions. Cortagen is the isolated synthetic tetrapeptide (AEDP) derived through analysis of Cortexin. They share a developmental origin but are chemically and regulatorily distinct.

Has Cortagen been studied in human cognitive decline?

Not in controlled trials accessible through the Western literature. Animal and in vitro data from the Khavinson group suggest neurophysiological effects, but there are no published randomized controlled trials assessing Cortagen in patients with cognitive impairment, dementia, or any human neurological condition.

What should I know about the evidence quality for Cortagen?

The evidence base is at an early preclinical stage. Most data come from a single research group in Russia. The microarray study in mice identified gene expression changes but did not establish functional outcomes. The epigenetic chromatin model is a theoretical framework rather than a proven mechanism in humans. Independent replication by separate laboratories has not been published.

References

1. Anisimov VN, Khavinson VKh, et al. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. Neuroendocrinol Lett. 2004;25(1-2):87-93. PMID 15159690. https://pubmed.ncbi.nlm.nih.gov/15159690/

2. Khavinson VKh et al. Epigenetic Regulation of "Aged" Heterochromatin by Peptide Bioregulator Cortagen. Int J Peptide Res Ther. 2014. https://link.springer.com/article/10.1007/s10989-014-9443-7